Adding Neoadjuvant and Adjuvant PD-1 Inhibitor to Neoadjuvant Chemotherapy Plus Concurrent Chemoradiotherapy in the Treatment of High-risk Nasopharyngeal Carcinoma
This is a randomized clinical trial comparing neoadjuvant and adjuvant PD-1 inhibitor Toripalimab plus neoadjuvant chemotherapy and concurrent chemoradiotherapy versus neoadjuvant chemotherapy and concurrent chemoradiotherapy alone in high-risk nasopharyngeal carcinoma
• Patients with newly histologically confirmed non-keratinizing nasopharyngeal carcinoma
• Clinical staged as T4 or N3 (according to the 8th AJCC edition)
• No evidence of distant metastasis (M0)
• Male and no pregnant female
• ECOG (Eastern Cooperative OncologyGroup) scale 0-1
• WBC ≥ 4×109 /L and PLT ≥4×109 /L and HGB ≥90 g/L
• Normal liver function test (ALT、AST ≤ 2.5×ULN, TBIL≤ 2.0×ULN)
• Normal renal function test ( creatinine clearance ≥60 ml/min)